Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
安珐布 (Anfabu), also known as Inosine and Amino Acids and Peptides for Injection (注射用肌氨肽苷), is a combination biological product developed and manufactured by Heilongjiang Jiangshi Pharmaceutical. It contains inosine, various amino acids, and peptides derived from animal tissues (typically porcine or bovine). The drug is primarily used in China as a neurotrophic and supportive treatment for a range of neurological and muscular conditions, including cerebral infarction, cerebral hemorrhage, traumatic brain injury, and muscle atrophy. While its exact molecular mechanism is not fully elucidated, it is thought to promote nerve cell metabolism, facilitate the repair of damaged neural tissue, and provide essential building blocks for protein synthesis in muscle and nerve cells. It is administered via intravenous or intramuscular injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inosine + amino acids + peptides.